Manuel Reina

Corporate Officer/Principal at University of Barcelona

Consumer Services

Health Technology

Profile

Manuel Reina is a Director of Advanced In Vitro Cell Technologies SL.
He is an Associate Professor of Cell Biology at the University of Barcelona.
He is a Co-Director of Celltec UB and a Member of the Origami Society.
Dr. Reina received a PhD in Molecular Biology from CSIC, Barcelona.

Manuel Reina active positions

Companies	Position	Start
University of Barcelona	Corporate Officer/Principal	-

All active positions of Manuel Reina

Former positions of Manuel Reina

Companies	Position	End
Advancell Advanced In Vitro Cell Technologies SL Advancell Advanced In Vitro Cell Technologies SL BiotechnologyHealth Technology Advancell Advanced In Vitro Cell Technologies SL is a holding company engaged in the design, development, and testing of pharmaceutical products. It focuses on indications in the areas of oncology, dermatology, and neurology. Its pipeline consists of medications for hand-food syndrome, chronic lymphocytic leukemia, multiple sclerosis, psoriasis, and myelodysplastic syndromes. These are then licensed to affiliates for manufacturing and distribution. The company was founded by Susana Castel-Gil, Senen Vilar, and Manuel Reina in 2001, and is headquartered in Barcelona, Spain.	Director/Board Member	-

See the detail of Manuel Reina's experience

Training of Manuel Reina

Consejo Superior de Investigaciones Científicas

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Manuel Reina's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Advancell Advanced In Vitro Cell Technologies SL Advancell Advanced In Vitro Cell Technologies SL BiotechnologyHealth Technology Advancell Advanced In Vitro Cell Technologies SL is a holding company engaged in the design, development, and testing of pharmaceutical products. It focuses on indications in the areas of oncology, dermatology, and neurology. Its pipeline consists of medications for hand-food syndrome, chronic lymphocytic leukemia, multiple sclerosis, psoriasis, and myelodysplastic syndromes. These are then licensed to affiliates for manufacturing and distribution. The company was founded by Susana Castel-Gil, Senen Vilar, and Manuel Reina in 2001, and is headquartered in Barcelona, Spain.	Health Technology